51 withdrawn. 51 Phase 3, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 51 | Withdrawn 51 |
| Phase 2 | 12 | Withdrawn 12 |
Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) Recombinant Hepatitis B new Bulk vaccine, DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine, Recombinant Hepatitis B vaccine (Registered BioFarma) - Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction | Phase 3 | Withdrawn | PT Bio Farma | 2025-12-01 | 2025-06-05 | |
| A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis Denifanstat, Placebo - MASH, NASH | Phase 3 | Withdrawn | Sagimet Biosciences Inc. | 2025-03-01 | 2025-05-15 | |
| A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH denifanstat, Placebo - MASLD, MASH | Phase 3 | Withdrawn | Sagimet Biosciences Inc. | 2025-03-01 | 2025-05-15 | |
| Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma Sitravatinib, Tislelizumab, sitravatinib-matching placebo - Hepatocellular Carcinoma | Phase 3 | Withdrawn | BeiGene | 2023-06-30 | 2023-06-07 | |
| BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases 4-Phenylbutyrate - Hereditary Diseases, Cholestasis, Intrahepatic | Phase 2 / Phase 3 | Withdrawn | Children's Hospital of Fudan University | 2023-02-08 | 2023-02-09 | |
| A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC HLX10, HLX04, Sorafenib - Hepatocellular Carcinoma (HCC) | Phase 3 | Withdrawn | Shanghai Henlius Biotech | 2022-11-15 | 2022-05-05 | |
| MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function MNK-6105, Placebo, Standard of Care - Hepatic Encephalopathy | Phase 3 | Withdrawn | Mallinckrodt | 2021-11-01 | 2021-09-22 | |
| Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility Rifaximin - Cirrhosis, Liver, Minimal Hepatic Encephalopathy | Phase 3 | Withdrawn | MetroHealth Medical Center | 2021-09-15 | 2025-12-24 | |
| Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection Lenvatinib, Nivolumab - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Withdrawn | Shi Ming | 2019-10-30 | 2020-01-09 | |
| HepATocellular Cancer Hcv Therapy Study Elbasvir / Grazoprevir Oral Tablet - Hepatocellular Carcinoma, Hepatoma | Phase 3 | Withdrawn | Bayside Health | 2019-09-01 | 2020-09-14 | |
| The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery Ropivacaine-Sufentanil, Dextrose 5 - Bowel Disease, Liver Diseases | Phase 2 / Phase 3 | Withdrawn | University of Alberta | 2019-08-01 | 2022-05-27 | |
| Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC Lenvatinib, PD-1 antibody, Placebo - Hepatocellular Carcinoma | Phase 3 | Withdrawn | Sun Yat-sen University | 2019-04-21 | 2019-05-02 | |
| Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria Lenvatinib, PD-1 antibody, TACE - Hepatocellular Carcinoma | Phase 3 | Withdrawn | Sun Yat-sen University | 2019-01-01 | 2019-05-02 | |
| Carvedilol vs Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding Carvedilol, Variceal band ligation - Portal Hypertension Related to Cirrhosis | Phase 3 | Withdrawn | Rutgers, The State University of New Jersey | 2018-07-01 | 2018-07-24 | |
| Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD) Ombitasvir/paritaprevir/ritonavir - Chronic Hepatitis C Virus | Phase 3 | Withdrawn | AbbVie | 2016-09-01 | 2016-12-05 | |
| Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients. Grazoprevir 100 mg/day, Elbasvir 50 mg/d, Elbasvir 50 mg/day - Liver Transplantation, Hepatitis C | Phase 3 | Withdrawn | Fundacion Clinic per a la Recerca Biomédica | 2016-08-03 | 2025-06-22 | |
| Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis Paeoniflorin + phosphatidylcholine or silymarin, Phosphatidylcholine or silymarin - Hepatitis, Autoimmune | Phase 3 | Withdrawn | Xiaoli Fan | 2016-08-01 | 2017-07-13 | |
| Transfer Factor Efficacy in the Management of Cirrhosis-associated Immune Dysfunction Human derived Transfer factor, Aqua pro injectione 4ml ampules for subcutaneous injection - Cirrhosis, Liver Failure | Phase 2 / Phase 3 | Withdrawn | Martin Janičko | 2016-07-01 | 2023-11-18 | |
| Cardiox Liver Function Test Pivotal Trial 0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose - Hepatic Failure, Liver Failure | Phase 3 | Withdrawn | Cardiox Corporation | 2015-11-01 | 2016-01-15 | |
| A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure Rifaximin, Lactulose - Hepatic Encephalopathy | Phase 3 | Withdrawn | NYU Langone Health | 2015-10-01 | 2016-03-02 |
Showing 20 of 51. Sign in to see all of them.
Carcinoma, Hepatocellular (15) · Hepatitis C, Chronic (10) · Hepatitis C (9) · Fibrosis (4) · Non-alcoholic Fatty Liver Disease (4) · Liver Cirrhosis (3) · Liver Failure (3) · Esophageal and Gastric Varices (2) · Fatty Liver (2) · Hepatic Encephalopathy (2) · Hepatitis B (2) · Hepatitis B, Chronic (2) · Hypertension, Portal (2) · Liver Failure, Acute (2)
Digestive System Diseases (51) · Hepatitis (23) · Blood-Borne Infections (22) · Communicable Diseases (22) · Hepatitis, Viral, Human (22) · Infections (22) · Virus Diseases (22) · Pathologic Processes (20) · Pathological Conditions, Signs and Symptoms (20) · Flaviviridae Infections (18) · RNA Virus Infections (18) · Adenocarcinoma (15) · Carcinoma (15) · Digestive System Neoplasms (15)
Ribavirin (12) · peginterferon alfa-2b (6) · peginterferon alfa-2a (5) · Oxaliplatin (4) · Fluorouracil (3) · Gemcitabine (3) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (3) · Rifaximin (3) · lenvatinib (3) · Folfox protocol (2) · Leucovorin (2) · Sorafenib (2) · TVB-2640 (2) · Vitamin D (2) · elbasvir-grazoprevir drug combination (2)
Guangxi Medical University (4) · Merck Sharp & Dohme LLC (4) · Boehringer Ingelheim (2) · Bristol-Myers Squibb (2) · Sagimet Biosciences Inc. (2) · Seoul National University Hospital (2) · Sun Yat-sen University (2) · ANRS, Emerging Infectious Diseases (1) · AbbVie (1) · Accuray Incorporated (1) · Albert Koong (1) · Bayside Health (1) · BeiGene (1) · Biotest Pharmaceuticals Corporation (1) · Cardiox Corporation (1)
China (8) · United States (8) · Egypt (3) · South Korea (3) · Canada (2) · India (2) · Spain (2) · Taiwan (2) · Australia (1) · Colombia (1) · Czechia (1) · Hong Kong (1) · Hungary (1) · Indonesia (1) · Ireland (1)
Lequn Li, PhD (3) · Ming Shi, MD (3) · Albert Koong (1) · Albert Koong, MD, PhD (1) · Arnaud Fontanet, MD, PhD (1) · Daniel Chang, MD (1) · Eddy Fadlyana, MD (1) · Fatima Higuera-de la Tijera, MD, MSc. (1) · Gamal Esmat, MD (1) · Gamal Esmat, MD, PhD (1)
PMID 19302262, PMID 20675008, PMID 20849805, PMID 21058409, PMID 21157444, PMID 23980077, PMID 25932262, PMID 26644276, PMID 33772456, PMID 40404984
2014 (1), 2015 (1), 2019 (1)